Fugro: A Contrarian Long Idea

Fugro's Q1 2024 results revealed weaker revenue and margins, though management is confident in meeting mid-term EBIT margin targets. Despite heavy capex, strong free cash flow generation has resulted in a healthy balance sheet, with net debt at 0.5x trailing EBITDA. The author views the current valuation as attractive, particularly in light of projected EBITDA growth by 2027, and considers a potential 2025 dip as a buying opportunity, estimating a fair value of €15.5-16 per share.

Analysis

Fugro's first-quarter 2024 results indicated a period of operational weakness, characterized by lower revenue and margins. Despite this short-term performance, the company's underlying financial health appears robust, underscored by strong free cash flow generation and a solid balance sheet. Notably, net debt stands at a very low 0.5x trailing EBITDA, a significant achievement considering the company's heavy capital expenditure program. The current valuation is presented as attractive, with the stock trading at a low EV/EBITDA multiple. This valuation is supported by consensus estimates which project significant EBITDA growth by 2027, creating a compelling long-term narrative. Management has reaffirmed its confidence in achieving mid-term EBIT margin targets, suggesting the recent margin pressure is viewed as temporary. The overall investment thesis frames any near-term price dips, potentially in 2025, as a strategic buying opportunity, with a fair value estimate cited at €15.5-€16 per share based on future cash flow analysis.

Key Decisions for Investors

• Investors with a long-term horizon should consider the recent weakness in revenue and margins as a potential entry point, given the company's strong balance sheet and attractive valuation.
• It is crucial to monitor upcoming quarterly reports for evidence of EBIT margin recovery to validate management's confidence and confirm that the Q1 performance was an anomaly.
• Evaluate the current EV/EBITDA multiple relative to peers and the company's own historical levels to assess the attractiveness of the valuation in the context of projected EBITDA growth through 2027.